Innovative Cancer CARE Test
In this video, William Lane spends about 27 minutes speaking on "Innovative Cancer CARE Test" at the 30th Annual Cancer Convention held on Labor Day weekend by the Cancer Control Society.
About William Lane
WILLIAM LANE, Ph.D. holds his B.S. and M.S. Degrees in Nutrition from Cornell University and his Ph.D. in Biochemistry and Nutrition from Rutgers University where he worked under two Nobel Prize winners. He recently was awarded the honorary degree of Doctor of Integrated Medicine from The Florida College of Integrative Medicine in Orlando, Florida where a new School of Naturapathic Medicine is being organized which will be named after Dr. Lane. In August of this year Dr. Lane was invited down to the South American nation of Peru to assist them in utilizing the plants and flora which were widely used by the Incas as effective medicines before the advent of Western Chemical Medicine.
Dr. Lane’s research is behind the interest in Shark Cartilage which is now the subject of a 600 patient, phase 3, seven million dollar study largely funded by the NIH and being run by the Mayo Clinic on advanced breast and colon cancer patients. Dr. Lane directed a human study which was successfully run in Cuba on 29 advanced cancer patients who had failed all conventional treatments and were receiving shark cartilage as the only medication. This was positively featured on CBS’s 60 Minutes with Mike Wallace in February and July 1993.
Dr. Lane has co-authored 4 books: Sharks Don’t Get Cancer (1993), Sharks Still Don’t Get Cancer (1996), The Skin Cancer Answer (1998) and Immune Power (1999). His work in Alternative Therapies and Anti-Aging has helped to increase the acceptance of natural treatments in complimenting mainstream medicine.
Transcription
It going to turn this on. Can you hear me? I said to Fritz here a few moments ago that I wasn't sure if Lorraine was punishing me or was trying to get me to bring out a big crowd. But I'm glad to see we have so many. Even though it's nine o'clock on a Sunday morning coming in on the airplane yesterday, I was amazed to read on Southwest. And they are magazine about they are pushing a new new medical device, a new medical discovery at. Era. Basically by five Marylee, you can hopefully cure them. I'm glad this is getting into so many new publications because I think by picking these things up early is a secret to much of the impending successful. Who are going to have this test that I'm going to talk about today is something that can enable us to pick up malignancies at a very early stage. Hopefully it will pick it up while you're still in a stage one, which will give today almost all the tests that are out there. Don't pick it up until you're in a stage three or stage four. And by that time, the opportunities for getting rid of it are are minimized. But this test will enable you. It still isn't approved by the FDA, but an IBC is in place. And for those of you who may get interested as a result of this talk, if they stop by the booth, they can get all the information, how they can join the ILB and have the tests performed on them and become part of the data that will go to the FDA eventually. The FDA is going. We're going to go with only with ovarian cancer, but actually this can pick up almost every type of malignancy. It's called a cab test for cancer. SeeI recognition tests are a big problem. I say is getting early detection.
I'm a take I can't meet the darn things. I'm getting old. So up again, early detection is the answer to two to two cancer. If you could get it early, you can generally defeat it.
They're asked to what they call screening tests. The mammography, the pap smear, the PSA, our screening test that will basically cover a big field.
Demography is what has basically brought down the deaths from breast cancer, which used to run about, oh forty six, forty seven thousand a year. It's now running around 40000 a year. So it is coming down, but there is a lot of false positives. And when you get a false positive test, the next thing you do is worry and get anxious. And before